International Journal of Radiation Oncology * Biology * Physics
Volume 61, Issue 1 , Pages 14-19 , January 2005

Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy

Accepted for poster presentation at the annual meeting of the American Radium Society, May 2004, Napa Valley, California.

  • Rex Cheung, M.D., Ph.D.

      Affiliations

    • Departments of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • Corresponding Author InformationReprint requests to: Rex Cheung, M.D., Ph.D., Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe, Box 97, Houston, TX, USA 77030. Tel: (713) 563-2339; Fax: (713)-563-2366;
    • ,
  • Susan L. Tucker, Ph.D.

      Affiliations

    • Biostatistics and Applied Mathematics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Andrew L. Lee, M.D.

      Affiliations

    • Departments of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Lei Dong, Ph.D.

      Affiliations

    • Radiation Physics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Ashish Kamat, M.D.

      Affiliations

    • Urology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Louis Pisters, M.D.

      Affiliations

    • Urology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Deborah A. Kuban, M.D.

      Affiliations

    • Departments of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Received 30 January 2004 ,Revised 23 April 2004 ,Accepted 26 April 2004.

References 

  1. Stamey TA, Yang N, Hay AR, et al.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–916
  2. Oesterling JE, Fuks Z, Lee CT, Scher HI. Cancer of the prostate. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer principles and practice of oncology. Philadelphia: Lippincott-Raven; 1997;p. 322–1385
  3. Hankey BF, Feuer EJ, Clegg LX, et al.  Cancer surveillance series (Interpreting trends in prostate cancer–part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates). J Natl Cancer Inst. 1999;91:1017–1024
  4. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: Interpreting trends in prostate cancer–part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999;91:1025–1032
  5. Etzioni R, Legler JM, Feuer EJ, et al.  Cancer surveillance series: Interpreting trends in prostate cancer–part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst. 1999;91:1033–1039
  6. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  7. American Society for Therapeutic Radiology and Oncology Consensus Panel . Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  8. Vicini FA, Kestin LL, Martinez AA. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45:553–561
  9. Kattan MW, Fearn PA, Leibel S, Potters L. The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48:1469–1474
  10. Hanlon AL, Diratzouian H, Hanks GE. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:297–303
  11. Horwitz EM, Uzzo RG, Hanlon AL, et al.  Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. J Urol. 2003;169:2153–2157
  12. Thames H, Kuban D, Levy L, et al.  Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003;57:929–943
  13. Cheung R, Tucker SL, Dong L, Kuban D. Dose–response for biochemical control among high-risk prostate cancer patients after external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:1234–1240
  14. Pollack A, Zagars GK. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys. 1997;39:1011–1018
  15. Brahme A. Dosimetric precision requirements in radiation therapy. Acta Radiol Oncol. 1984;23:379–391
  16. Carmelli D, Halpern J, Swan GE, et al.  27-year mortality in the Western Collaborative Group study: Construction of risk groups by recursive partitioning. J Clin Epidemiol. 1991;44:1341–1351
  17. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958;53:457–481
  18. Lilja H. Biology of prostate-specific antigen. Urology. 2003;62:27–33
  19. Rosser CJ, Kuban DA, Levy LB, et al.  Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol. 2002;168:2001–2005
  20. Petricoin EF, Ornstein DK, Paweletz CP, et al.  Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst. 2002;94:1576–1578
  21. Partin AW, Pound CR, Clemens JQ, et al.  Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years. Urol Clinics North Am. 1993;20:713–725
  22. Pollack A, Zagars GK, Starkschall G, et al.  Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  23. Kuban DA, el-Mahdi AM, Schellhammer PF. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 1995;32:307–316
  24. Zagars GK, Pollack A, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1999;44:809–819
  25. Pilepich MV, Winter K, John MJ, et al.  Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243–1252
  26. Bolla M, Collette L, Blank L, et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet. 2002;360:103–106
  27. Basaria S, Lieb J, Tang AM, et al.  Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol. 2002;56:779–786
  28. Hanks GE, Hanlon AL, Pinover WH, et al.  Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys. 2000;46:823–832
  29. Kupelian PA, Mohan DS, Lyons J, et al.  Higher than standard radiation doses (> or = 72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phy. 2000;46:567–574
  30. Zelefsky MJ, Fuks Z, Hunt M, et al.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876–881
  31. Zelefsky MJ, Fuks Z, Hunt M, et al.  High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111–1116
  32. Leibel SA, Fuks Z, Zelefsky MJ, et al.  Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer. Semin Oncol. 2003;30:596–615
  33. Fuks Z, Leibel SA, Wallner KE, et al.  The effect of local control on metastatic dissemination in carcinoma of the prostate (Long-term results in patients treated with 125I implantation). Int J Radiat Oncol Biol Phys:. 1991;21:537–547

PII: S0360-3016(04)00769-2

doi: 10.1016/j.ijrobp.2004.04.064

International Journal of Radiation Oncology * Biology * Physics
Volume 61, Issue 1 , Pages 14-19 , January 2005

Article Tools

* Image Usage & Resolution